Skip to content

No OS benefit to adding bendamustine to rituximab for marginal zone lymphoma
Tri-specifc CAR-T shows early activity in B-cell malignancies
Can PFS predict treatment-related overall survival in MCL?
SOHO Insider 2026 print issue May/June
What are the barriers to research in the community oncology setting?

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Loretta Nastoupil, MD

Cellular Therapy

Loretta Nastoupil, MD

Leukemia

Loretta Nastoupil, MD

Lymphoma

Loretta Nastoupil, MD

Multiple Myeloma

Loretta Nastoupil, MD

Myelodysplastic Syndromes

Loretta Nastoupil, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

May 25, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Loretta Nastoupil, MD

Loretta Nastoupil, MD

by Mark Bland
November 25, 2025
0 Comments
Less than a minute
492 Views
6 months ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

keyboard

Lymphoma, Indolent B-Cell Lymphomas

No OS benefit to adding bendamustine to rituximab for marginal zone lymphoma

May 22, 2026

AACR 2026, Cellular Therapy, Video Interviews

Tri-specifc CAR-T shows early activity in B-cell malignancies

May 21, 2026

Young scientists conducting research investigations in a medical laboratory, a researcher in the foreground is using a microscope

Mantle Cell Lymphoma, News

Can PFS predict treatment-related overall survival in MCL?

May 20, 2026

Soho Print

SOHO Insider 2026 print issue May/June

May 19, 2026

Trending now, Community Oncology, Leukemia, Myelodysplastic Syndromes, Video Interviews

What are the barriers to research in the community oncology setting?

May 18, 2026

AACR 2026, Cellular Therapy, Multiple Myeloma, News, Video Interviews

Drs. Ghobrial and Nadeem discuss results from the phase II CAR-PRISM trial

May 15, 2026

Top Categories

Cellular Therapy

72

Leukemia

111

Lymphoma

123

Multiple Myeloma

94

Myelodysplastic Syndromes

39

Myeloproliferative Neoplasms

22

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Loretta Nastoupil, MD

Cellular Therapy

Loretta Nastoupil, MD

Leukemia

Loretta Nastoupil, MD

Lymphoma

Loretta Nastoupil, MD

Multiple Myeloma

Loretta Nastoupil, MD

Myelodysplastic Syndromes

Loretta Nastoupil, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

keyboard

No OS benefit to adding bendamustine to rituximab for marginal zone lymphoma

Tri-specifc CAR-T shows early activity in B-cell malignancies

Young scientists conducting research investigations in a medical laboratory, a researcher in the foreground is using a microscope

Can PFS predict treatment-related overall survival in MCL?

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.